Not necessarily the strongest absolute response. The most rational target could be the one where the difference in efficacy between Coramsine and the current best treatment is greatest. This presumably needs also to be blended with market potential to arrive at the optimal target.
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-8
Add to My Watchlist
What is My Watchlist?